涂层血小板水平升高与非腔隙性梗死患者脑卒中复发的关系研究
|
摘要
目的研究涂层血小板水平升高与非腔隙性梗死患者脑卒中复发的关系。方法分析180例非腔隙性梗死患者涂层血小板水平,随访时间12个月。研究对象根据涂层血小板水平分为3组,对每组应用累积事件曲线估计复发脑卒中的时间分布,应用对数秩检验进行比较分析。结果 3组非腔隙性梗死患者12个月复发脑卒中累积事件存在差异。结论本研究提示涂层血小板水平升高与非腔隙性梗死患者的卒中复发有关,检测涂层血小板水平可作为预测非腔隙性梗死患者脑卒中复发风险的一种方法。
Objective To observe the relationship between elevated coated platelet level and stroke recurrence in patients with non-lacular cerebral infarction.Methods Coated platelet levels were analyzed in 180 patients with non-lacunar infarction and followed up for 12 months.The subjects were divided into three groups according to the coated platelet level.The cumulative event curve was used to estimate the time distribution of recurrent stroke in each group,and the log-rank test was used for comparison.Results There were differences in the cumulative events of 12-month recurrent stroke in the three groups of patients with non-lacular cerebral infarction.Conclusion This study suggests that elevated coated platelet levels are associated with stroke recurrence in patients with non-lacular cerebral infarction.Detection of coated platelet levels can be used as a predictor of risk of stroke recurrence in patients with non-lacular cerebral infarction.
Objective To observe the relationship between elevated coated platelet level and stroke recurrence in patients with non-lacular cerebral infarction.Methods Coated platelet levels were analyzed in 180 patients with non-lacunar infarction and followed up for 12 months.The subjects were divided into three groups according to the coated platelet level.The cumulative event curve was used to estimate the time distribution of recurrent stroke in each group,and the log-rank test was used for comparison.Results There were differences in the cumulative events of 12-month recurrent stroke in the three groups of patients with non-lacular cerebral infarction.Conclusion This study suggests that elevated coated platelet levels are associated with stroke recurrence in patients with non-lacular cerebral infarction.Detection of coated platelet levels can be used as a predictor of risk of stroke recurrence in patients with non-lacular cerebral infarction.
引文
[1]周锦霞,李国珍,程伟,等.大动脉粥样硬化型脑梗死与穿支动脉疾病型脑梗死的临床特点对比[J].重庆医学,2017,46(4):513-516.
[2]王文芳.氯吡格雷联合拜阿司匹林对急性脑梗死患者血小板聚集及血液流变学的影响[J].中国医学工程,2018,26(1):56-58.
[3]张文昭,乔雪竹,李家琪,等.皮质下型分水岭脑梗死发病机制与临床特点研究进展[J].中华老年心脑血管病杂志,2018,20(1):105-107.
[4]李永琴,陈飞,张微微,等.脑微出血与脑梗死的相关性研究[J].中华老年心脑血管病杂志,2017,19(6):615-618.
[5]周锦霞,李国珍,程伟,等.大动脉粥样硬化型脑梗死与穿支动脉疾病型脑梗死的临床特点对比[J].重庆医学,2017,46(4):513-516.
[6]莫志怀,陈瑶,王俊峰,等.高血压合并急性脑梗死患者血清细胞因子及同型半胱氨酸与脑梗死的关系[J].中国实用神经疾病杂志,2017,20(3):4-7.
[7]夏楠,任彩丽,王红星,等.脑梗死急性期康复训练流程对患者运动功能和日常生活活动能力改善程度的影响[J].中国康复医学杂志,2017,32(4):396-401.
[8]LASTRAPES K K,MOHAMMED B M,Mazepa M A,et al.Coated platelets and severe haemophilia A bleeding phenotype:Is there a connection?[J].Haemophilia,2016,22(1):148-151.
[9]MATTHEIJ N J,SWIERINGA F,MASTENBROEK T G.Coated platelets function in platelet-dependent fibrin formation via integrinαIIbβ3 and transglutaminase factor XIII[J].Haematologica,2016,101(4):427-436.
[10]KIRKPATRICK A C,TAFUR A J,VINCENT A S.Coated-platelets improve prediction of stroke and transient ischemic attack in asymptomatic internal carotid artery stenosis[J].Stroke,2014,45(10):2 995-3 001.
[11]PRODAN C I,DALE G L.Coated-platelets in ischemic stroke-potential insight into the etiology of stroke subtypes[J].Int J Stroke,2008,3(4):249-250.
[12]SUSREE M,PANTELEEV M A,ANAND M.Coated platelets introduce significant delay in onset of peak thrombin production:Theoretical predictions[J].J Theor Biol,2018,14(453):108-116.
[13]KIRKPATRICK A C,VINCENT A S,DALE G L,et al.Coated-platelets predict stroke at 30days following TIA[J].Neurology,2017,89(2):125-128.
[14]KNUDSEN T,KJALKE M,TRANHOLM M,et al.Development of a flow cytometric assay for detection of coated platelets in dogs and evaluation of binding of coated platelets to recombinant human coagulation factor VIIa[J].Am J Vet Res,2011,72(8):1 007-1 014.
[15]KIRKPATRICK A C,STONER J A,DALE G L,et al.Elevated coated-platelets in symptomatic large-artery stenosis patients are associated with early stroke recurrence[J].Platelets,2014,25(2):93-96.
[16]UNSWORTH A J,BYE A P,TANNETTA D S,et al.Farnesoid X Receptor and Liver X Receptor Ligands Initiate Formation of Coated Platelets[J].Arterioscler Thromb Vasc Biol,2017,37(8):1 482-1 493.
[17]KOTOVA Y N,ATAULLAKHANOV F I,PANTELEEV M A.Formation of coated platelets is regulated by the dense granule secretion of adenosine 5'diphosphate acting via the P2Y12receptor[J].J Thromb Haemost,2008,6(9):1 603-1 635.
[18]PRODAN C I,VINCENT A S,KIRKPATRICK A C,et al.Higher levels of coated-platelets are observed in patients with subarachnoid hemorrhage but lower levels are associated with increased mortality at 30days[J].J Neurol Sci,2013,334(1-2):126-129.
[19]HOEMBERG M,STAHL D,SCHLENKE P,et al.The isotype of autoantibodies influences the phagocytosis of antibody-coated platelets in autoimmune thrombocytopenic purpura[J].Scand J Immunol,2011,74(5):489-495.
[20]SABOUR S.Letter by Sabour regarding article,"coatedplatelets improve prediction of stroke and transient ischemic attack in asymptomatic internal carotid artery stenosis"[J].Stroke,2015,46(2):e46.
[21]DING D.Molecular insights into aneurysmal subarachnoid hemorrhage and cerebral vasospasm from analysis of coated-platelets[J].J Neurol Sci,2014,338(1/2):236.
[22]KIRKPATRICK A C,TAFUR A J,PRODAN C I.Response to letter regarding article,"coated-platelets improve prediction of stroke and transient ischemic attack in asymptomatic internal carotid artery stenosis"[J].Stroke,2015,46(2):e47.
[23]PRODAN C I.Response to letter to the editor from Dr,Dale Ding:molecular insights into aneurysmal subarachnoid hemorrhage and cerebral vasospasm from analysis of coated-platelets[J].J Neurol Sci,2014,338(1/2):237.
[24]DALE G L,REMENYI G,FRIESE P.Tetraspanin CD9is required for microparticle release from coatedplatelets[J].Platelets,2009,20(6):361-366.
[25]BROOKS M B,CATALFAMO J L,FRIESE P,et al,Scott syndrome dogs have impaired coated-platelet formation and calcein release but normal mitochondrial depolarization[J].J Thromb Haemostasis,2007,5(11):1 972-1 974.
[26]REMENYI G,SZASZ R,FRIESE P,et al,Role of mitochondrial permeability transition pore in coatedplatelet formation[J].Arterioscler Thromb Vasc Biol,2005,25(3):467-471.
[27]郑硕,张允岭,孙静宜,等.动脉粥样硬化与缺血性卒中的关系及中医证候要素演变分析[J].世界中医药,2017,12(3):655-660;665.
[28]袁婷婷,邹晓毅.脑梗死继发癫(癎)的研究进展[J].中华老年心脑血管病杂志,2012,14(3):330-332.
[29]侯晓雯,王冲,陈欣,等.中国人群H型高血压与脑梗死关系的Meta分析[J].中国全科医学,2015,19(11):1232-1 235;1 239.
[30]江颖,方兴,张永全,等.活血化瘀法治疗缺血性卒中的研究进展[J].世界中医药,2016,11(5):936-940.
[31]曾倩龙,秀英宋,春江.复发性脑梗死相关危险因素分析[J].中国实用神经疾病杂志,2018,21(1):37-39.
[32]吴新莹,许冬梅,王心军.复发性脑梗死患者发生阿司匹林抵抗的相关因素研究[J].贵州医药,2017,41(7):713-715.
[33]刘楠,于颖,李冰.复发性脑梗死患者血流变学改变的临床分析[J].临床医学研究与实践,2017,2(7):21-22.
[34]张瑜,程曼,姚源蓉.复发性脑梗死患者发生早期神经功能恶化的相关危险因素分析[J].实用医学杂志,2016,32(7):1 037-1 040.
[35]解力,蔡秀英.复发性脑梗死的血管病因学研究进展[J].中国康复理论与实践,2015,21(11):1 264-1 266.
[36]于彤政.脑梗死患者抗血小板二级预防后再发脑梗死的类型及危险因素分析[J].中国实用医药,2018,13(8):37-38.
[37]陈芳,杨永贵,郭岗.磁共振扩散峰度成像预测急性脑梗死预后的初步研究[J].磁共振成像,2018,9(2):127-132.
[38]汪可可,武建辉,周莹.基于BP神经网络的急性脑梗死患者自发性出血性转化的风险预测研究[J].磁共振成像,2018,21(12):1 413-1 418.
[39]代鸣明,于航,苏庆杰.血清同型半胱氨酸与神经元特异性烯醇化酶联合检测对进展性脑梗死的预测价值[J].贵州医科大学学报,2018,43(8):1-5.
[40]王启章,张祥钦,李玉浩.弥散张量纤维束成像技术对脑梗死早期神经功能恶化的预测性作用研究[J].中华老年心脑血管病杂志,2018,20(7):737-741.
[41]焦冬生,赵全钱,时德,等.替罗非班联合奥扎格雷纳治疗进展性脑卒中的临床疗效及其对血小板水平影响分析[J].贵州医药,2018,42(1):39-41.
[42]何娴,叶晓冰,陈家钖,等.脑卒中患者载脂蛋白E基因多态性与血小板水平相关性研究[J].黑龙江医药,2018,31(1):118-120.
[43]杨波.双联抗血小板治疗在缺血性脑卒中患者二级预防中的应用及远期心血管事件影响[J].内蒙古医学杂志,2018,50(3):332-334.
[44]程颜梅.脑卒中患者认知功能障碍发生情况及其机制[J].山东医药,2016,56(28):83-85.
[45]刘明月.氯吡格雷联合阿司匹林治疗进展性缺血性脑卒中的临床观察[J].现代诊断与治疗,2018,29(3):377-378.
[46]李慧梅.双联抗血小板治疗改善后循环缺血性脑卒中预后临床观察[J].河南医学研究,2017,26(2):269-270.
[47]王坤,段毅,王军英,等.阿司匹林联合氯吡格雷治疗对缺血性脑卒中病人神经功能及血小板聚集率的影响[J].中西医结合心脑血管病杂志,2017,15(17):2 207-2 209.
[48]余强.双联抗血小板治疗非心源性缺血性脑卒中的效果观察[J].临床合理用药杂志,2017,10(14):31-32.
[49]付刚,夏豪,朱小山.平均血小板容积预测非瓣膜性心房颤动并发缺血性脑卒中的价值[J].广西医学,2016,38(4):464-466;470.
[50]黄晓红.双联抗血小板治疗对后循环缺血性脑卒中患者的预后结局的影响[J].标记免疫分析与临床,2016,23(2):170-173.
[51]张晓琳,赵丽娜.中青年缺血性脑血管疾病与血浆高同型半胱氨酸和血小板水平的相关性研究[J].中国保健营养,2016,26(8):46-47.
[52]周建平,单湘湘,范仁根.缺血性脑卒中老年患者血浆血小板活化因子乙酰水解酶与胰岛素抵抗关系的研究[J].河北医科大学学报,2018,39(5):523-527.
[53]黄耀忠.首次及复发脑卒中患者血小板相关参数及颈动脉斑块形成的临床研究[J].血栓与止血学,2016,22(5):518-520.
[54]马素霞,吴慧颖.不同双联抗血小板方案对急性冠状动脉综合征合并2型糖尿病患者经皮冠状动脉介入术后残余血小板高反应性及主要心血管不良事件与出血事件风险的影响[J].心肺血管病杂志,2018,37(2):91-94.
[55]李俊艺,梁晖,陈甦,等.中药方剂对缺血性卒中患者血小板活化、内皮功能、炎症反应的影响研究[J].中外医学研究,2016,14(36):38-39;40.
[56]邱峰,吴越,曹辉,等.双抗血小板对进展性脑卒中患者的脑血流动力学及血小板参数影响的研究[J].医学研究生学报,2017,30(10):1 065-1 070.
[57]张楚,金平.进展性缺血性脑卒中患者血小板参数的临床分析[J].安徽卫生职业技术学院学报,2016,15(5):28-29.
[58]张立娜.强化抗血小板治疗联合阿托伐他汀预防社区缺血性脑卒中复发的临床效果观察[J].基层医学论坛,2017,21(32):4 442-4 444.
[59]吴松伟,李桂英.替罗非班联合奥扎格雷钠对进展性缺血性脑卒中患者神经功能和血小板功能的影响研究[J].实用心脑肺血管病杂志,2016,24(4):35-38;39.
[60]刘昌云,陈龙飞,陈枝挺,等.症状性颈动脉狭窄患者延长双联抗血小板治疗临床观察[J].福建医科大学学报,2017,51(1):35-39.
[61]张朝华,刘旭帮,郝冬琴.脑卒中后新发房颤对其复发的影响[J].中国实用神经疾病杂志,2018,21(9):952-955.
[62]葛海梅.急性缺血性脑卒中复发危险因素分析及低密度脂蛋白与高密度脂蛋白比值对脑卒中复发的预测价值[J].中西医结合心血管病电子杂志,2017,5(27):38.
[63]徐雷,齐江彤,陈伟良.青年急性缺血性脑卒中患者急性期血压水平与脑卒中复发的相关性分析[J].现代实用医学,2017,29(1):50-51;89.
[64]林彩云.复发危险因素及LDL/HDL比值等危险因素对急性出血性脑卒中复发的预测分析[J].锦州医科大学学报,2018,39(2):55-57.
[65]王婷婷,陈玮琪,王伊龙.缺血性脑卒中的精准抗血小板治疗[J].精准医学杂志,2018,33(1):86-91.
[66]王雅婵,张博爱.脑卒中复发的相关危险因素分析[J].河南医学研究,2017,26(20):3 685-3 686.
[67]覃祖业,梁朝莹,颜循金,等.不同抗血小板药物联合他汀类药物治疗对缺血性脑卒中复发率的影响[J].中国老年学杂志,2018,38(3):534-535.
[68]吴铮铮,马懿,周华,等.门诊健康宣教在脑卒中复发危险因素干预中的效果分析[J].现代医药卫生,2018,34(13):2 074-2 076.
[69]覃祖业,梁朝莹,颜循金,等.ESSEN中风风险评估量表对预测缺血性脑卒中复发的价值[J].中外医学研究,2018,16(6):32-33.
[70]张彩润.高尿酸血症与缺血性脑卒中复发的相关性分析[J].世界复合医学,2017,3(1):73-75.
[71]李振迟,陈欣,张伟.他汀类药物联合阿司匹林预防脑卒中复发的meta分析[J].安徽卫生职业技术学院学报,2017,16(5):46-48.
[72]安雅臣,程焱,王玉浔,等.缺血性脑卒中3年复发危险因素的Cox回归分析及预测模型的构建[J].中华行为医学与脑科学杂志,2017,26(6):544-548.
[73]狄子晖,杨静.缺血性脑卒中二级预防中血小板功能与缺血性血管事件复发的相关性[J].海南医学,2017,28(5):807-809.
[74]刘辉,周实华,孔智慧.点时间尿蛋白与尿肌酐比值在糖尿病脑卒中复发的价值分析[J].当代医学,2017,23(32):119-120.
[75]成卓霖.卡托普利降低脑梗死复发危险因素的研究[J].中国医药科学,2017,7(7):253-256.
[76]朱昌亮,何喜东.西尼地平与氨氯地平对脑卒中伴高血压患者肾功能的保护及脑卒中二级预防作用比较[J].中国乡村医药,2017,24(16):12-13.
[77]巫碧佳,赵旭,区腾飞,等.阻塞性睡眠呼吸暂停低通气综合征与短暂性脑缺血发作及轻型卒中复发的关系[J].临床内科杂志,2018,35(4):241-244.
[78]戴颖仪,黄志新,刘新通,等.影响大动脉粥样硬化性脑梗死复发的危险因素[J].南方医科大学学报,2017,37(12):1 678-1 682.
[79]王光胜,王元伟,常春红,等.改良ABCD3评分对短暂性脑缺血发作患者脑卒中复发风险的评估价值[J].中华老年心脑血管病杂志,2017,19(7):689-693.
[80]阿地力江·阿布力米提,努尔比亚·阿不拉江.颈动脉颅外段狭窄介入治疗对脑卒中预后的影响[J].中国继续医学教育,2017,9(24):81-82.
[81]王芳,姚治平.脑梗死患者5年复发的相关因素研究[J].中国医药导报,2018,15(2):67-70,82.
[82]安雅臣,王玉浔,程焱.缺血性脑卒中复发模型的构建及其前瞻性预测分析[J].中华老年心脑血管病杂志,2017,19(7):685-688.
[2]王文芳.氯吡格雷联合拜阿司匹林对急性脑梗死患者血小板聚集及血液流变学的影响[J].中国医学工程,2018,26(1):56-58.
[3]张文昭,乔雪竹,李家琪,等.皮质下型分水岭脑梗死发病机制与临床特点研究进展[J].中华老年心脑血管病杂志,2018,20(1):105-107.
[4]李永琴,陈飞,张微微,等.脑微出血与脑梗死的相关性研究[J].中华老年心脑血管病杂志,2017,19(6):615-618.
[5]周锦霞,李国珍,程伟,等.大动脉粥样硬化型脑梗死与穿支动脉疾病型脑梗死的临床特点对比[J].重庆医学,2017,46(4):513-516.
[6]莫志怀,陈瑶,王俊峰,等.高血压合并急性脑梗死患者血清细胞因子及同型半胱氨酸与脑梗死的关系[J].中国实用神经疾病杂志,2017,20(3):4-7.
[7]夏楠,任彩丽,王红星,等.脑梗死急性期康复训练流程对患者运动功能和日常生活活动能力改善程度的影响[J].中国康复医学杂志,2017,32(4):396-401.
[8]LASTRAPES K K,MOHAMMED B M,Mazepa M A,et al.Coated platelets and severe haemophilia A bleeding phenotype:Is there a connection?[J].Haemophilia,2016,22(1):148-151.
[9]MATTHEIJ N J,SWIERINGA F,MASTENBROEK T G.Coated platelets function in platelet-dependent fibrin formation via integrinαIIbβ3 and transglutaminase factor XIII[J].Haematologica,2016,101(4):427-436.
[10]KIRKPATRICK A C,TAFUR A J,VINCENT A S.Coated-platelets improve prediction of stroke and transient ischemic attack in asymptomatic internal carotid artery stenosis[J].Stroke,2014,45(10):2 995-3 001.
[11]PRODAN C I,DALE G L.Coated-platelets in ischemic stroke-potential insight into the etiology of stroke subtypes[J].Int J Stroke,2008,3(4):249-250.
[12]SUSREE M,PANTELEEV M A,ANAND M.Coated platelets introduce significant delay in onset of peak thrombin production:Theoretical predictions[J].J Theor Biol,2018,14(453):108-116.
[13]KIRKPATRICK A C,VINCENT A S,DALE G L,et al.Coated-platelets predict stroke at 30days following TIA[J].Neurology,2017,89(2):125-128.
[14]KNUDSEN T,KJALKE M,TRANHOLM M,et al.Development of a flow cytometric assay for detection of coated platelets in dogs and evaluation of binding of coated platelets to recombinant human coagulation factor VIIa[J].Am J Vet Res,2011,72(8):1 007-1 014.
[15]KIRKPATRICK A C,STONER J A,DALE G L,et al.Elevated coated-platelets in symptomatic large-artery stenosis patients are associated with early stroke recurrence[J].Platelets,2014,25(2):93-96.
[16]UNSWORTH A J,BYE A P,TANNETTA D S,et al.Farnesoid X Receptor and Liver X Receptor Ligands Initiate Formation of Coated Platelets[J].Arterioscler Thromb Vasc Biol,2017,37(8):1 482-1 493.
[17]KOTOVA Y N,ATAULLAKHANOV F I,PANTELEEV M A.Formation of coated platelets is regulated by the dense granule secretion of adenosine 5'diphosphate acting via the P2Y12receptor[J].J Thromb Haemost,2008,6(9):1 603-1 635.
[18]PRODAN C I,VINCENT A S,KIRKPATRICK A C,et al.Higher levels of coated-platelets are observed in patients with subarachnoid hemorrhage but lower levels are associated with increased mortality at 30days[J].J Neurol Sci,2013,334(1-2):126-129.
[19]HOEMBERG M,STAHL D,SCHLENKE P,et al.The isotype of autoantibodies influences the phagocytosis of antibody-coated platelets in autoimmune thrombocytopenic purpura[J].Scand J Immunol,2011,74(5):489-495.
[20]SABOUR S.Letter by Sabour regarding article,"coatedplatelets improve prediction of stroke and transient ischemic attack in asymptomatic internal carotid artery stenosis"[J].Stroke,2015,46(2):e46.
[21]DING D.Molecular insights into aneurysmal subarachnoid hemorrhage and cerebral vasospasm from analysis of coated-platelets[J].J Neurol Sci,2014,338(1/2):236.
[22]KIRKPATRICK A C,TAFUR A J,PRODAN C I.Response to letter regarding article,"coated-platelets improve prediction of stroke and transient ischemic attack in asymptomatic internal carotid artery stenosis"[J].Stroke,2015,46(2):e47.
[23]PRODAN C I.Response to letter to the editor from Dr,Dale Ding:molecular insights into aneurysmal subarachnoid hemorrhage and cerebral vasospasm from analysis of coated-platelets[J].J Neurol Sci,2014,338(1/2):237.
[24]DALE G L,REMENYI G,FRIESE P.Tetraspanin CD9is required for microparticle release from coatedplatelets[J].Platelets,2009,20(6):361-366.
[25]BROOKS M B,CATALFAMO J L,FRIESE P,et al,Scott syndrome dogs have impaired coated-platelet formation and calcein release but normal mitochondrial depolarization[J].J Thromb Haemostasis,2007,5(11):1 972-1 974.
[26]REMENYI G,SZASZ R,FRIESE P,et al,Role of mitochondrial permeability transition pore in coatedplatelet formation[J].Arterioscler Thromb Vasc Biol,2005,25(3):467-471.
[27]郑硕,张允岭,孙静宜,等.动脉粥样硬化与缺血性卒中的关系及中医证候要素演变分析[J].世界中医药,2017,12(3):655-660;665.
[28]袁婷婷,邹晓毅.脑梗死继发癫(癎)的研究进展[J].中华老年心脑血管病杂志,2012,14(3):330-332.
[29]侯晓雯,王冲,陈欣,等.中国人群H型高血压与脑梗死关系的Meta分析[J].中国全科医学,2015,19(11):1232-1 235;1 239.
[30]江颖,方兴,张永全,等.活血化瘀法治疗缺血性卒中的研究进展[J].世界中医药,2016,11(5):936-940.
[31]曾倩龙,秀英宋,春江.复发性脑梗死相关危险因素分析[J].中国实用神经疾病杂志,2018,21(1):37-39.
[32]吴新莹,许冬梅,王心军.复发性脑梗死患者发生阿司匹林抵抗的相关因素研究[J].贵州医药,2017,41(7):713-715.
[33]刘楠,于颖,李冰.复发性脑梗死患者血流变学改变的临床分析[J].临床医学研究与实践,2017,2(7):21-22.
[34]张瑜,程曼,姚源蓉.复发性脑梗死患者发生早期神经功能恶化的相关危险因素分析[J].实用医学杂志,2016,32(7):1 037-1 040.
[35]解力,蔡秀英.复发性脑梗死的血管病因学研究进展[J].中国康复理论与实践,2015,21(11):1 264-1 266.
[36]于彤政.脑梗死患者抗血小板二级预防后再发脑梗死的类型及危险因素分析[J].中国实用医药,2018,13(8):37-38.
[37]陈芳,杨永贵,郭岗.磁共振扩散峰度成像预测急性脑梗死预后的初步研究[J].磁共振成像,2018,9(2):127-132.
[38]汪可可,武建辉,周莹.基于BP神经网络的急性脑梗死患者自发性出血性转化的风险预测研究[J].磁共振成像,2018,21(12):1 413-1 418.
[39]代鸣明,于航,苏庆杰.血清同型半胱氨酸与神经元特异性烯醇化酶联合检测对进展性脑梗死的预测价值[J].贵州医科大学学报,2018,43(8):1-5.
[40]王启章,张祥钦,李玉浩.弥散张量纤维束成像技术对脑梗死早期神经功能恶化的预测性作用研究[J].中华老年心脑血管病杂志,2018,20(7):737-741.
[41]焦冬生,赵全钱,时德,等.替罗非班联合奥扎格雷纳治疗进展性脑卒中的临床疗效及其对血小板水平影响分析[J].贵州医药,2018,42(1):39-41.
[42]何娴,叶晓冰,陈家钖,等.脑卒中患者载脂蛋白E基因多态性与血小板水平相关性研究[J].黑龙江医药,2018,31(1):118-120.
[43]杨波.双联抗血小板治疗在缺血性脑卒中患者二级预防中的应用及远期心血管事件影响[J].内蒙古医学杂志,2018,50(3):332-334.
[44]程颜梅.脑卒中患者认知功能障碍发生情况及其机制[J].山东医药,2016,56(28):83-85.
[45]刘明月.氯吡格雷联合阿司匹林治疗进展性缺血性脑卒中的临床观察[J].现代诊断与治疗,2018,29(3):377-378.
[46]李慧梅.双联抗血小板治疗改善后循环缺血性脑卒中预后临床观察[J].河南医学研究,2017,26(2):269-270.
[47]王坤,段毅,王军英,等.阿司匹林联合氯吡格雷治疗对缺血性脑卒中病人神经功能及血小板聚集率的影响[J].中西医结合心脑血管病杂志,2017,15(17):2 207-2 209.
[48]余强.双联抗血小板治疗非心源性缺血性脑卒中的效果观察[J].临床合理用药杂志,2017,10(14):31-32.
[49]付刚,夏豪,朱小山.平均血小板容积预测非瓣膜性心房颤动并发缺血性脑卒中的价值[J].广西医学,2016,38(4):464-466;470.
[50]黄晓红.双联抗血小板治疗对后循环缺血性脑卒中患者的预后结局的影响[J].标记免疫分析与临床,2016,23(2):170-173.
[51]张晓琳,赵丽娜.中青年缺血性脑血管疾病与血浆高同型半胱氨酸和血小板水平的相关性研究[J].中国保健营养,2016,26(8):46-47.
[52]周建平,单湘湘,范仁根.缺血性脑卒中老年患者血浆血小板活化因子乙酰水解酶与胰岛素抵抗关系的研究[J].河北医科大学学报,2018,39(5):523-527.
[53]黄耀忠.首次及复发脑卒中患者血小板相关参数及颈动脉斑块形成的临床研究[J].血栓与止血学,2016,22(5):518-520.
[54]马素霞,吴慧颖.不同双联抗血小板方案对急性冠状动脉综合征合并2型糖尿病患者经皮冠状动脉介入术后残余血小板高反应性及主要心血管不良事件与出血事件风险的影响[J].心肺血管病杂志,2018,37(2):91-94.
[55]李俊艺,梁晖,陈甦,等.中药方剂对缺血性卒中患者血小板活化、内皮功能、炎症反应的影响研究[J].中外医学研究,2016,14(36):38-39;40.
[56]邱峰,吴越,曹辉,等.双抗血小板对进展性脑卒中患者的脑血流动力学及血小板参数影响的研究[J].医学研究生学报,2017,30(10):1 065-1 070.
[57]张楚,金平.进展性缺血性脑卒中患者血小板参数的临床分析[J].安徽卫生职业技术学院学报,2016,15(5):28-29.
[58]张立娜.强化抗血小板治疗联合阿托伐他汀预防社区缺血性脑卒中复发的临床效果观察[J].基层医学论坛,2017,21(32):4 442-4 444.
[59]吴松伟,李桂英.替罗非班联合奥扎格雷钠对进展性缺血性脑卒中患者神经功能和血小板功能的影响研究[J].实用心脑肺血管病杂志,2016,24(4):35-38;39.
[60]刘昌云,陈龙飞,陈枝挺,等.症状性颈动脉狭窄患者延长双联抗血小板治疗临床观察[J].福建医科大学学报,2017,51(1):35-39.
[61]张朝华,刘旭帮,郝冬琴.脑卒中后新发房颤对其复发的影响[J].中国实用神经疾病杂志,2018,21(9):952-955.
[62]葛海梅.急性缺血性脑卒中复发危险因素分析及低密度脂蛋白与高密度脂蛋白比值对脑卒中复发的预测价值[J].中西医结合心血管病电子杂志,2017,5(27):38.
[63]徐雷,齐江彤,陈伟良.青年急性缺血性脑卒中患者急性期血压水平与脑卒中复发的相关性分析[J].现代实用医学,2017,29(1):50-51;89.
[64]林彩云.复发危险因素及LDL/HDL比值等危险因素对急性出血性脑卒中复发的预测分析[J].锦州医科大学学报,2018,39(2):55-57.
[65]王婷婷,陈玮琪,王伊龙.缺血性脑卒中的精准抗血小板治疗[J].精准医学杂志,2018,33(1):86-91.
[66]王雅婵,张博爱.脑卒中复发的相关危险因素分析[J].河南医学研究,2017,26(20):3 685-3 686.
[67]覃祖业,梁朝莹,颜循金,等.不同抗血小板药物联合他汀类药物治疗对缺血性脑卒中复发率的影响[J].中国老年学杂志,2018,38(3):534-535.
[68]吴铮铮,马懿,周华,等.门诊健康宣教在脑卒中复发危险因素干预中的效果分析[J].现代医药卫生,2018,34(13):2 074-2 076.
[69]覃祖业,梁朝莹,颜循金,等.ESSEN中风风险评估量表对预测缺血性脑卒中复发的价值[J].中外医学研究,2018,16(6):32-33.
[70]张彩润.高尿酸血症与缺血性脑卒中复发的相关性分析[J].世界复合医学,2017,3(1):73-75.
[71]李振迟,陈欣,张伟.他汀类药物联合阿司匹林预防脑卒中复发的meta分析[J].安徽卫生职业技术学院学报,2017,16(5):46-48.
[72]安雅臣,程焱,王玉浔,等.缺血性脑卒中3年复发危险因素的Cox回归分析及预测模型的构建[J].中华行为医学与脑科学杂志,2017,26(6):544-548.
[73]狄子晖,杨静.缺血性脑卒中二级预防中血小板功能与缺血性血管事件复发的相关性[J].海南医学,2017,28(5):807-809.
[74]刘辉,周实华,孔智慧.点时间尿蛋白与尿肌酐比值在糖尿病脑卒中复发的价值分析[J].当代医学,2017,23(32):119-120.
[75]成卓霖.卡托普利降低脑梗死复发危险因素的研究[J].中国医药科学,2017,7(7):253-256.
[76]朱昌亮,何喜东.西尼地平与氨氯地平对脑卒中伴高血压患者肾功能的保护及脑卒中二级预防作用比较[J].中国乡村医药,2017,24(16):12-13.
[77]巫碧佳,赵旭,区腾飞,等.阻塞性睡眠呼吸暂停低通气综合征与短暂性脑缺血发作及轻型卒中复发的关系[J].临床内科杂志,2018,35(4):241-244.
[78]戴颖仪,黄志新,刘新通,等.影响大动脉粥样硬化性脑梗死复发的危险因素[J].南方医科大学学报,2017,37(12):1 678-1 682.
[79]王光胜,王元伟,常春红,等.改良ABCD3评分对短暂性脑缺血发作患者脑卒中复发风险的评估价值[J].中华老年心脑血管病杂志,2017,19(7):689-693.
[80]阿地力江·阿布力米提,努尔比亚·阿不拉江.颈动脉颅外段狭窄介入治疗对脑卒中预后的影响[J].中国继续医学教育,2017,9(24):81-82.
[81]王芳,姚治平.脑梗死患者5年复发的相关因素研究[J].中国医药导报,2018,15(2):67-70,82.
[82]安雅臣,王玉浔,程焱.缺血性脑卒中复发模型的构建及其前瞻性预测分析[J].中华老年心脑血管病杂志,2017,19(7):685-688.